The effect of oral magnesium supplementation on acute non-specific low back pain: Prospective randomized clinical trial

Bayram, Serkan; Şahin, Koray; Anarat, Fikret Berkan; Chousein, Chasan Memet; Kocazeybek, Bekir; Altan, Murat; Akgül, Turgut

doi:10.1016/j.ajem.2021.03.078

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further 21 studies were excluded as they did not report quantitative data on the outcomes of interest. Finally, data from 18 RCTs were available for this work (“Comparative Study On Efficacy Of Aceclofenac And Aceclofenac Plus Tizanidine In Patients With Low Back Pain At Nepal Medical College And Teaching …,” 36–52 ). The flow chart of the literature search is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review

Baroncini

Maffulli

Al-Zyoud

et al. 2023

Journal Orthopaedic Research

View full text Add to dashboard Cite

Acute low back pain (LBP) imposes a significant socioeconomical burden as it is the condition that, worldwide, cause the most disability. Nonetheless, the literature regarding the best pharmacological management of acute LBP is limited, and the indications available in the literature are conflicting. This work investigates whether the pharmacological management of acute LBP can effectively reduce pain and disability, and aims to identify which drugs show the highest efficacy. This systematic review was conducted according to the 2020 PRISMA statement. In September 2022, PubMed, Scopus, and Web of Science were accessed. All the randomized controlled trials investigating the efficacy of myorelaxants, nonsteroidal anti-inflammatory drugs (NSAIDs), and paracetamol for acute LPB were accessed. Only studies that investigated the lumbar spine were included. Only studies reporting on patients with acute LBP with symptom duration of less than 12 weeks were included. Only patients older than 18 years and with nonspecific low back pain were included. Studies that investigated the use of opioids in acute LBP were not considered. Data from 18 studies and 3478 patients were available. Myorelaxants and NSAIDs were effective in reducing pain and disability in acute LBP at approximately one week. The combination of NSAIDs and paracetamol was associated with a greater improvement than the use of NSAIDs alone, but paracetamol alone did not induce any significant improvement. Placebo was not effective in reducing pain. Clinical Significance: Myorelaxants, NSAIDs, and NSAIDs with paracetamol could reduce pain and disability in patients with acute LBP.acute, low back pain, lumbago, management | INTRODUCTIONLow back pain (LBP) is the musculoskeletal condition that causes the most disability worldwide. 1 The rate of first-ever episodes reaches 15%, with 80% of subjects experiencing an activity-imitating recurrence within 1 year. [2][3][4] In the United States, 25% of patients interviewed regarding common causes of pain reported having suffered from LBP in the 3 months before receiving the questionnaire. 5 LBP is defined as acute when symptoms last 2-12 weeks, 6,7 but up to 60% of patients will develop chronic LBP. 8,9 As first

show abstract

Section: Resultsmentioning

confidence: 99%

Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review

Baroncini

Maffulli

Al-Zyoud

et al. 2023

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…Out of 26 studies in Table 3, 19 were randomized placebo-controlled trials [83,86,[190][191][192][193][194][195][196][197][198][199][200][201][202][203][204][205][206]] and three were randomized controlled trials without a placebo group [207][208][209]. The remaining studies had varying designs [132,[210][211][212]. Dosage and duration of magnesium supplementation varied significantly across studies, ranging from 10 days to 32 weeks, and various magnesium sources were utilized, including Mg oxide, Mg sulfate, Mg citrate, Mg lactate, and chelated forms like Mg creatine chelate and Mg bisglycinate chelate.…”

Section: Magnesium and Muscle Health: Evidence From Human Studiesmentioning

confidence: 99%

“…Studies also explored magnesium's role in clinical populations, including patients with alcoholic liver disease [190], chronic alcoholism [193], and chronic or acute musculoskeletal low back pain [205,210]. While benefits in muscle strength were not observed in patients with alcoholic liver disease [190], improvements in muscle strength were noted in chronic alcoholics [193].…”

Section: Magnesium and Muscle Health: Evidence From Human Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The Integral Role of Magnesium in Muscle Integrity and Aging: A Comprehensive Review

Souza,

Vasconcelos,

Dias

et al. 2023

Nutrients

View full text Add to dashboard Cite

Aging is characterized by significant physiological changes, with the degree of decline varying significantly among individuals. The preservation of intrinsic capacity over the course of an individual’s lifespan is fundamental for healthy aging. Locomotion, which entails the capacity for independent movement, is intricately connected with various dimensions of human life, including cognition, vitality, sensory perception, and psychological well-being. Notably, skeletal muscle functions as a pivotal nexus within this intricate framework. Any perturbation in its functionality can manifest as compromised physical performance and an elevated susceptibility to frailty. Magnesium is an essential mineral that plays a central role in approximately 800 biochemical reactions within the human body. Its distinctive physical and chemical attributes render it an indispensable stabilizing factor in the orchestration of diverse cellular reactions and organelle functions, thereby rendering it irreplaceable in processes directly impacting muscle health. This narrative review offers a comprehensive exploration of the pivotal role played by magnesium in maintaining skeletal muscle integrity, emphasizing the critical importance of maintaining optimal magnesium levels for promoting healthy aging.

show abstract

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Cao,

Han,

et al. 2024

Drugs

View full text Add to dashboard Cite

Background and Objective Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its effectiveness in managing low back pain and osteoarthritis is unclear. This systematic review investigated whether paracetamol combination therapy is more effective and safer than monotherapy or placebo in low back pain and osteoarthritis. Methods Online database searches were conducted for randomised trials that evaluated paracetamol combined with another analgesic compared to a placebo or the non-paracetamol ingredient in the combination (monotherapy) in low back pain and osteoarthritis. The primary outcome was a change in pain. Secondary outcomes were (serious) adverse events, changes in disability and quality of life. Follow-up was immediate (≤ 2 weeks), short (> 2 weeks but ≤ 3 months), intermediate (> 3 months but < 12 months) or long term (≥ 12 months). A random-effects meta-analysis was conducted. Risk of bias was assessed using the original Cochrane tool, and quality of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results Twenty-two studies were included. Pain was reduced with oral paracetamol plus a non-steroidal anti-inflammatory drug (NSAID) at immediate term in low back pain (paracetamol plus ibuprofen vs ibuprofen [mean difference (MD) − 6.2, 95% confidence interval (CI) −10.4 to −2.0, moderate evidence]) and in osteoarthritis (paracetamol plus aceclofenac vs aceclofenac [MD − 4.7, 95% CI − 8.3 to − 1.2, moderate certainty evidence] and paracetamol plus etodolac vs etodolac [MD − 15.1, 95% CI − 18.5 to − 11.8; moderate certainty evidence]). Paracetamol plus oral tramadol reduced pain compared with placebo at intermediate term for low back pain (MD − 11.7, 95% CI − 19.2 to − 4.3; very low certainty evidence) and osteoarthritis (MD − 6.8, 95% CI − 12.7 to −0.9; moderate certainty evidence). Disability scores improved in half the comparisons. Quality of life was infrequently measured. All paracetamol plus NSAID combinations did not increase the risk of adverse events compared to NSAID monotherapy. Conclusions Low-to-moderate quality evidence supports the oral use of some paracetamol plus NSAID combinations for short-term pain relief with no increased risk of harm for low back pain and osteoarthritis compared to its non-paracetamol monotherapy comparator.

show abstract

The effect of oral magnesium supplementation on acute non-specific low back pain: Prospective randomized clinical trial

Cited by 5 publications

References 24 publications

Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review

Nonopioid pharmacological management of acute low back pain: A level I of evidence systematic review

The Integral Role of Magnesium in Muscle Integrity and Aging: A Comprehensive Review

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Contact Info

Product

Resources

About